Klein AK

Gilgamesh Pharmaceuticals, New York, NY, USA.

9 papers · ORCID

ArticlePsilocybin

An exploration of the relationships between the effects of psilocybin on behavior, 5-HT<sub>2A</sub> receptor occupancy, and neuroplastic effects in mice.

Maltby CJ, Klein AK, Paschen E +6

Europe PMC2026
ArticlePsilocybin

A novel psychedelic 5-HT<sub>2A</sub> receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.

Marek GJ, Makai-Bölöni S, Umbricht D +16

Europe PMC2026
ArticlePsilocybin

Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice.

Noback M, Kenton JA, Klein AK +5

Europe PMC2025
ArticlePsychedelics

Identification of 5-HT<sub>2A</sub> receptor signaling pathways associated with psychedelic potential.

Wallach J, Cao AB, Calkins MM +16

Europe PMC2023
ArticlePsilocybin

Investigation of the Structure-Activity Relationships of Psilocybin Analogues.

Klein AK, Chatha M, Laskowski LJ +5

Europe PMC2021
ArticleLSD

Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD).

Brandt SD, Kavanagh PV, Westphal F +8

Europe PMC2020
ArticlePsilocybin

Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin.

Sherwood AM, Halberstadt AL, Klein AK +4

Europe PMC2020
ArticlePsilocybin

Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.

Halberstadt AL, Chatha M, Klein AK +2

Europe PMC2020
ArticleLSD

Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).

Halberstadt AL, Chatha M, Klein AK +5

Europe PMC2020